Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.58 |
| ▸ | BTK | Q06187 | 6/20 | 0.55 |
| ▸ | EGFR | P00533 | 5/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | HCK | P08631 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 3/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.53 |
| ▸ | PRKDC | P78527 | 3/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863865 | 0.88 | RET (0.58) | RET | |
| SCHEMBL863508 | 0.88 | RET (0.71) | RETEGFRPIK3CDABL1HCK | |
| SCHEMBL863781 | 0.85 | RET (0.55) | RETBTKEGFRPIK3CDABL1 | |
| SCHEMBL17090629 | 0.84 | BTK (0.61) | RETBTKEGFRABL1HCK | |
| SCHEMBL15451261 | 0.78 | BTK (0.41) | RETBTKEGFRPIK3CDABL1 | |
| SCHEMBL19775208 | 0.78 | RET (0.61) | RET | |
| SCHEMBL19303914 | 0.78 | RET (0.64) | RET | |
| SCHEMBL19732745 | 0.77 | RET (0.63) | RET | |
| SCHEMBL17235723 | 0.76 | BTK (0.69) | BTKEGFRPIK3CDABL1HCK | |
| SCHEMBL14617696 | 0.76 | RET (0.53) | RETEGFRPIK3CDABL1HCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642606-B2 | ZAP-70 active compounds | PLEXXIKON INC. (US) | 2014-02-04 | — | — | US | claimed |
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2012-03-29 | — | — | US | claimed |
| US-8642606-B2 | ZAP-70 active compounds | PLEXXIKON INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642606-B2 | ZAP-70 active compounds | PLEXXIKON INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642606-B2 | ZAP-70 active compounds | PLEXXIKON INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077827-A1 | ZAP-70 ACTIVE COMPOUNDS | ZAP70, PRKCZ, PRKDC | RET 469/4885BTK 13/4885EGFR 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.